Search Results 271-280 of 16561 for ������������KA���:ZA31���24������ ���������������������������������
... KA, Fuentes Bayne HE, Rwigema JCM, Patel SH ... 2025; 36(1):14-24. Epub 2024 Aug 09. Calcano GA ... 2021 Jul; 82 (Suppl 3):e138-e147 Epub 2020 Jan 24
2020 Feb 11; 117 (6):3053-3062 Epub 2020 Jan 24. View PubMed; Shomorony I ... KE, Brar P, Kahn AM, Spector TD, Caskey CT, Venter JC, Karow DS, Kirkness ...
Jacksonville, Florida: 24-007139. About this study. The purpose of this study is to use Canine Assisted Therapy (CAT) in patients undergoing office procedures ...
Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might ...
The study will assess proteinuria by 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment. Participation eligibility.
Subjects receiving treatment with sotatercept are eligible only if on a stable dose of sotatercept for at least 24 weeks prior to and throughout Screening ...
Jacksonville, Florida: 24-004337; Scottsdale/Phoenix, Arizona: 24-004337. NCT ID: NCT06223516. Sponsor Protocol Number: M23-001. About this study. The purpose ...
Rochester, Minnesota: 24-004371. NCT ID: NCT06723015. About this study. The purpose of this study is to evaluate change in tau PET in patients receiving anti ...
Rochester, Minnesota: 24-004354. About this study. The purpose of this study is to evaluate the incidence of surgical outpatients that accept the invitation ...
Rochester, Minnesota: 24-006211. About this study. The purpsoe of this study is to screen the community for heart issues, by completing a questionnaire ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.